Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Open accessThe DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Abstract
Alcohol use disorder (AUD) is a highly prevalent but severely under-treated disorder, with only three widely-approved pharmacotherapies. Given that AUD is a very heterogeneous disorder, it is unlikely that one single medication will be effective for all individuals with an AUD. As such, there is a need to develop new, more effective, and diverse pharmacological treatment options for AUD with the hopes of increasing utilization and improving care. In this qualitative literature review, we discuss the efficacy, mechanism of action, and tolerability of approved, repurposed, and novel pharmacotherapies for the treatment of AUD with a clinical perspective. Pharmacotherapies discussed include: disulfiram, acamprosate, naltrexone, nalmefene, topiramate, gabapentin, varenicline, baclofen, sodium oxybate, aripiprazole, ondansetron, mifepristone, ibudilast, suvorexant, prazosin, doxazosin, N-acetylcysteine, GET73, ASP8062, ABT-436, PF-5190457, and cannabidiol. Overall, many repurposed and novel agents discussed in this review demonstrate clinical effectiveness and promise for the future of AUD treatment. Importantly, these medications also offer potential improvements towards the advancement of precision medicine and personalized treatment for the heterogeneous AUD population. However, there remains a great need to improve access to treatment, increase the menu of approved pharmacological treatments, and de-stigmatize and increase treatment-seeking for AUD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Similarly, the efficacy of naltrexone and acamprosate are also suspected and inconclusive for preventing relapse in AUD [55].”
From Research protocol of the efficacy of probiotics for the treatment of alcohol use disorder among adult males: A comparison with placebo and acceptance and commitment therapy in a randomized controlled trial (2023) · cites this paper as [55]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reductions in SUD severity were also found, suggesting improvements in SUD-related consequences and functioning.”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While alcohol abstinence is desirable as the ultimate outcome of AUD treatment, only 16% of patients with AUD are able to achieve abstinence [55].”
From Research protocol of the efficacy of probiotics for the treatment of alcohol use disorder among adult males: A comparison with placebo and acceptance and commitment therapy in a randomized controlled trial (2023) · cites this paper as [55]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a type of alcohol antagonist, disulfiram causes patients to experience strong physical discomfort after ingesting a small amount of alcohol, which may place patient at risk of the disulfiram-ethanol interaction reaction, at high risk of non-compliance and cannot effectively reduce craving, so it is basically not a preferred treatment for AUD unless supervised treatment with disulfiram can be”
From Research protocol of the efficacy of probiotics for the treatment of alcohol use disorder among adult males: A comparison with placebo and acceptance and commitment therapy in a randomized controlled trial (2023) · cites this paper as [55]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The US Food and Drug Administration (FDA) has approved three drugs for abstinence: disulfiram, naltrexone and acamprosate.”
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479 · cited 1×
“Ghrelin, a peptide produced by endocrine cells primarily in the stomach [261], is thought to regulate growth hormone secretion, food intake, and glucose homeostasis [262].”
BackgroundHasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908 · cited 8×
“Furthermore, the lag between the age at which AUD onsets and the age of first AUD treatment has been estimated to be eight years on average [7].”
BackgroundInfluentialGrant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0584 · Cited by 2,556 · cited 3×
“Alcohol use disorder (AUD) is a highly prevalent, chronic, relapsing condition characterized by an impaired ability to stop or control alcohol use despite clinically significant impairment, distress, or other adverse consequences [1, 2].”
BackgroundInfluentialPertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930 · cited 1×
“In particular, a large scale trial (COMBINE), which compared acamprosate, naltrexone, and behavioral therapies, both individually and combined with each other, against placebo (N = 1383), found that acamprosate had no significant effect on drinking in comparison to placebo, either alone or in combination with naltrexo…”
BackgroundNaltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Degenhardt, L., Charlson, F., Ferrari, A., Santomauro, D., Erskine, H., Mantilla-Herrara, A., Whiteford, H., Leung, J., Naghavi, M., Griswold, M., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30337-7 · Cited by 1,572 · cited 1×
“4 million people globally were estimated to have an AUD [3].”
BackgroundNaltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487 · cited 1×
“In 1994, the FDA approved oral naltrexone to treat alcohol dependence after two independent 12-week trials, which included 97 and 70 participants, respectively, found that naltrexone significantly decreased drinking days and relapse rates [52, 53].”
BackgroundIs there a common molecular pathway for addiction?
Nestler, E. J. (2005) · Nature Neuroscience · doi:10.1038/nn1578 · Cited by 1,388 · cited 1×
“By attenuating alcohol-induced opioidergic activity in the mesolimbic dopamine system, opioid antagonists like naltrexone, modulate the rewarding effects of alcohol (mediated by dopamine), thereby reducing alcohol consumption [50, 51].”
Background2010 National and State Costs of Excessive Alcohol Consumption
Sacks, J. J., Gonzales, K. R., Bouchery, E. E., Tomedi, L. E., & Brewer, R. D. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.05.031 · Cited by 1,180 · cited 7×
“An estimated 44.6 million adults per year in the USA suffer from AUD, and 93.4 million (approximately 33”
BackgroundInfluentialCannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039 · cited 1×
“CB1 and CB2 receptors [274, 275], and blocking anandamide update and inhibiting enzymatic hydrolysis [276].”
BackgroundMüller, T. D., Nogueiras, R., Andermann, M. L., Andrews, Z. B., Anker, S. D., Argente, J., Batterham, R. L., Benoit, S. C., Bowers, C. Y., Broglio, F., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.03.005 · Cited by 1,034
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923 · cited 3×
“to significantly reduce both the risk of return to any drinking and return to binge drinking [36]; however, both of these associations were modest in magnitude [64].”
BackgroundAgonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878 · cited 1×
“CBD may also interact with non-endocannabinoid signaling systems, including the serotonergic system [277] and the opioidergic system [278], among others.”
BackgroundOral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743 · cited 2×
“Clinical studies have found that topiramate reduced craving and alcohol drinking in a sample of 150 participants over 12 weeks [112], and decreased drinking days, heavy-drinking days, and number of drinks per day in a sample of 85 participants in a 14-week trial [116].”
BackgroundAddolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., Mirijello, A., Abenavoli, L., D'Angelo, C., Caputo, F., Zambon, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61814-5 · Cited by 685 · cited 2×
“Of the non-FDA medications that may prove useful in this population, only baclofen has been evaluated in an RCT [94].”
BackgroundThe mechanisms of action of gabapentin and pregabalin
SILLS, G. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.11.003 · Cited by 671 · cited 1×
“It is thought to modulate GABA activity by indirectly interacting with voltage-gated calcium channels [122].”
BackgroundGarbutt, J. C., Kranzler, H. R., O’Malley, S. S., Gastfriend, D. R., Pettinati, H. M., Silverman, B. L., Loewy, J. W., Ehrich, E. W., & Vivitrex Study Group, F. T. (2005) · JAMA · doi:10.1001/jama.293.13.1617 · Cited by 635
Excitation of Ventral Tegmental Area Dopaminergic and Nondopaminergic Neurons by Orexins/Hypocretins
Korotkova, T. M., Sergeeva, O. A., Eriksson, K. S., Haas, H. L., & Brown, R. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00007.2003 · Cited by 583 · cited 1×
“The dense orexin projections from the lateral hypothalamus to the ventral tegmental area provide neurobiological support that orexins may influence responses to rewarding stimuli, including alcohol [227, 228].”
BackgroundDiagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review
Kranzler, H. R., & Soyka, M. (2018) · JAMA · doi:10.1001/jama.2018.11406 · Cited by 580 · cited 3×
“Acamprosate is generally well tolerated [34] and may also have neuroprotective effects [45, 46].”
BackgroundStahre, M., Roeber, J., Kanny, D., Brewer, R. D., & Zhang, X. (2014) · Preventing Chronic Disease · doi:10.5888/pcd11.130293 · Cited by 562 · cited 1×
“In the USA alone, AUD is estimated to contribute to about 88,000 deaths each year [5].”
BackgroundGabapentin for chronic neuropathic pain in adults
Wiffen, P. J., Derry, S., Bell, R. F., Rice, A. S., Tölle, T. R., Phillips, T., & Moore, R. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub4 · Cited by 561 · cited 1×
“The most common adverse events associated with gabapentin treatment are somnolence, dizziness, peripheral edema, and ataxia or gait disorder [136].”
BackgroundTopiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542 · cited 1×
“A large, multisite 14-week RCT that enrolled 371 participants with alcohol dependence found reductions in heavy-drinking days and improvements in various self-reported drinking-related outcomes [117].”
BackgroundCarmen, B., Angeles, M., Ana, M., & María, A. J. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00763.x · Cited by 504 · cited 1×
“Additional recent trials demonstrate that naltrexone reduces the rewarding effects of alcohol [54, 55], alcohol craving [40, 56], drinks per drinking day [57], and relapse rates [58, 59], strengthening the initial findings.”
O'Malley, S., Krishnan-Sarin, S., Farren, C., Sinha, R., & Kreek, M. (2002) · Psychopharmacology · doi:10.1007/s002130100919 · Cited by 492 · cited 1×
“Additional recent trials demonstrate that naltrexone reduces the rewarding effects of alcohol [54, 55], alcohol craving [40, 56], drinks per drinking day [57], and relapse rates [58, 59], strengthening the initial findings.”
Mann, K., Bladström, A., Torup, L., Gual, A., & van den Brink, W. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.020 · Cited by 484
Addolorato, G. (2002) · Alcohol and Alcoholism · doi:10.1093/alcalc/37.5.504 · Cited by 481
Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence
Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999) · JAMA · doi:10.1001/jama.281.14.1318 · Cited by 444
Psychiatric comorbidities in alcohol use disorder
Castillo-Carniglia, A., Keyes, K. M., Hasin, D. S., & Cerdá, M. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30222-6 · Cited by 444 · cited 4×
“These trials include samples with comorbid psychopathology (i.e., PTSD) and will use neuroimaging methods to examine the neural circuitry underlying NAC’s modulation of relevant metabolites and neural reactivity to alcohol cues.”
BackgroundInfluentialEthanol withdrawal seizures and the NMDA receptor complex
Grant, K. A., Valverius, P., Hudspith, M., & Tabakoff, B. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90022-x · Cited by 431 · cited 1×
“As chronic alcohol abuse is associated with neuronal changes related to NMDA receptors, this neuroprotection may be particularly important in AUD treatment [47, 48].”
BackgroundDisulfiram Treatment of Alcoholism: A Veterans Administration Cooperative Study
Fuller, R. K. (1986) · JAMA · doi:10.1001/jama.1986.03380110055026 · Cited by 431
Requirement of central ghrelin signaling for alcohol reward
Jerlhag, E., Egecioglu, E., Landgren, S., Salomé, N., Heilig, M., Moechars, D., Datta, R., Perrissoud, D., Dickson, S. L., & Engel, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812809106 · Cited by 424
Johnson, B. A., Roache, J. D., Javors, M. A., DiClemente, C. C., Cloninger, C. R., Prihoda, T. J., Bordnick, P. S., Ait-Daoud, N., & Hensler, J. (2000) · JAMA · doi:10.1001/jama.284.8.963 · Cited by 414
Acamprosate for alcohol dependence
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004332.pub2 · Cited by 412
Gual, A., He, Y., Torup, L., van den Brink, W., & Mann, K. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.02.006 · Cited by 407
The orexin system regulates alcohol-seeking in rats
Lawrence, A. J., Cowen, M. S., Yang, H., Chen, F., & Oldfield, B. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706789 · Cited by 392
Gabapentin misuse, abuse and diversion: A systematic review
Smith, R. V., Havens, J. R., & Walsh, S. L. (2016) · Addiction · doi:10.1111/add.13324 · Cited by 378 · cited 1×
“Notably, gabapentin does carry the potential for misuse and abuse, particularly in individuals with opioid use disorders [137]; therefore, recommendation of gabapentin to individuals with comorbid substance use disorder should be carefully considered.”
BackgroundCannabidiol is an allosteric modulator at mu- and delta-opioid receptors
Kathmann, M., Flau, K., Redmer, A., Tränkle, C., & Schlicker, E. (2006) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-006-0033-x · Cited by 377 · cited 1×
“CBD may also interact with non-endocannabinoid signaling systems, including the serotonergic system [277] and the opioidergic system [278], among others.”
BackgroundReus, V. I., Fochtmann, L. J., Bukstein, O., Eyler, A. E., Hilty, D. M., Horvitz-Lennon, M., Mahoney, J., Pasic, J., Weaver, M., Wills, C. D., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.1750101 · Cited by 372 · cited 3×
“Another anti-convulsant medication, gabapentin, is also suggested by the APA for use in AUD treatment with the goal of reducing alcohol consumption or achieving abstinence [107].”
BackgroundInfluentialSteensland, P., Simms, J. A., Holgate, J., Richards, J. K., & Bartlett, S. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705368104 · Cited by 365
Nakamura, T., Uramura, K., Nambu, T., Yada, T., Goto, K., Yanagisawa, M., & Sakurai, T. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02555-5 · Cited by 351 · cited 1×
“The dense orexin projections from the lateral hypothalamus to the ventral tegmental area provide neurobiological support that orexins may influence responses to rewarding stimuli, including alcohol [227, 228].”
BackgroundDisulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis
Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H.-J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087366 · Cited by 347 · cited 1×
“A meta-analysis of 22 RCTs found that disulfiram saw increased success rates compared to placebo in open-label studies only—blinded trials yielded no statistical significance between disulfiram and placebo [29].”
BackgroundHurd, Y. L., Spriggs, S., Alishayev, J., Winkel, G., Gurgov, K., Kudrich, C., Oprescu, A. M., & Salsitz, E. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18101191 · Cited by 343 · cited 1×
“Two recent studies investigated signals for potential efficacy of CBD as a treatment for heroin use disorder [281] and cannabis use disorder [282].”
BackgroundGabapentin Treatment for Alcohol Dependence: A Randomized Clinical Trial
Mason, B. J., Quello, S., Goodell, V., Shadan, F., Kyle, M., & Begovic, A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11950 · Cited by 340 · cited 1×
“In a proof-of-concept one-week human laboratory trial (N = 33), participants treated with gabapentin showed significant decreases in alcohol craving in comparison to placebo [128], and a follow-up 12-week RCT with 150 participants found that gabapentin significantly increased abstinence rates and percentage of no heav…”
BackgroundHeterogeneity of Alcohol Use Disorder: Understanding Mechanisms to Advance Personalized Treatment
Litten, R. Z., Ryan, M. L., Falk, D. E., Reilly, M., Fertig, J. B., & Koob, G. F. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12669 · Cited by 330
van den Brink, W., Aubin, H.-J., Bladstrom, A., Torup, L., Gual, A., & Mann, K. (2013) · Alcohol and Alcoholism · doi:10.1093/alcalc/agt061 · Cited by 305
Rösner, S., Leucht, S., Lehert, P., & Soyka, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107078308 · Cited by 300 · cited 1×
“Acamprosate is recommended for the achievement and maintenance of complete abstinence, rather than for the reduction of drinking or prevention of relapse in the event of drinking [49].”
BackgroundVarenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers
McKee, S. A., Harrison, E. L. R., O'Malley, S. S., Krishnan-Sarin, S., Shi, J., Tetrault, J. M., Picciotto, M. R., Petrakis, I. L., Estevez, N., & Balchunas, E. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.029 · Cited by 298 · cited 1×
“A human laboratory study with 20 heavy-drinking smokers on varenicline for 7 days found that varenicline significantly reduced the number of drinks consumed and increased the likelihood of complete abstinence in the human laboratory paradigm [146].”
BackgroundGarbutt, J. C., Kampov‐Polevoy, A. B., Gallop, R., Kalka‐Juhl, L., & Flannery, B. A. (2010) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01273.x · Cited by 294
Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., et al. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31829623f4 · Cited by 287 · cited 2×
“Moderator analyses of data collected in the above multisite trial [142] indicated that varenicline was more efficacious in reducing drinking among smokers who also reduced their cigarette smoking [147] and among individuals with lower severity of AUD, such that that varenicline significantly reduced percent heavy-drin…”
BackgroundPhase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
Fox, R. J., Coffey, C. S., Conwit, R., Cudkowicz, M. E., Gleason, T., Goodman, A., Klawiter, E. C., Matsuda, K., McGovern, M., Naismith, R. T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803583 · Cited by 286
Modulation of High‐Voltage–Activated Calcium Channels in Dentate Granule Cells by Topiramate
Zhang, X., Velumian, A. A., Jones, O. T., & Carlen, P. L. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb02173.x · Cited by 276 · cited 1×
“However, the drug is thought to inhibit glutamate α-amino 3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) and kainate receptors [108–110] and L-type calcium channels [111], as well as enhance the inhibitory activity of GABA [109].”
BackgroundAcamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat
Spanagel, R., Hölter, S. M., Allingham, K., Landgraf, R., & Zieglgänsberger, W. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00174-4 · Cited by 274
DOUBLE-BLIND RANDOMIZED MULTICENTRE TRIAL OF ACAMPROSATE IN MAINTAINING ABSTINENCE FROM ALCOHOL
(1995) · Alcohol and Alcoholism · doi:10.1093/oxfordjournals.alcalc.a045720 · Cited by 273
Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings
Johnson, B. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.005 · Cited by 264 · cited 1×
“Although the specific mechanism of action remains under investigation, ondansetron may address serotonergic dysfunction common in early-onset AUD [163, 164], and may reduce alcohol craving via 5-HT3 projections to dopaminergic connections in the midbrain.”
BackgroundMyrick, H., Anton, R. F., Li, X., Henderson, S., Randall, P. K., & Voronin, K. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.4.466 · Cited by 258 · cited 1×
“Another combination study in 90 participants after 7 days on ondansetron and naltrexone found that the combination decreased craving for alcohol and ventral striatal activation to alcohol cues [171].”
BackgroundRay, L. A., & Hutchison, K. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.9.1069 · Cited by 258 · cited 1×
“Additional recent trials demonstrate that naltrexone reduces the rewarding effects of alcohol [54, 55], alcohol craving [40, 56], drinks per drinking day [57], and relapse rates [58, 59], strengthening the initial findings.”
Self-citationRehm, J., Shield, K. D., Gmel, G., Rehm, M. X., & Frick, U. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.08.001 · Cited by 257 · cited 5×
“Placebo effects in this trial may explain some of these negative outcomes, as might differences in trial design and patient characteristics: COMBINE required 4 days of pre-trial abstinence while European trials with positive outcomes were typically conducted in inpatient populations requiring complete detoxification […”
BackgroundInfluentialOpioid antagonists for alcohol dependence
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Vecchi, S., Srisurapanont, M., & Soyka, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867.pub3 · Cited by 247 · cited 1×
“Oral and injectable naltrexone show similar decreases in likelihood of binge drinking [65] and both are generally well tolerated, with fairly mild side effects [66].”
BackgroundAlcohol and opioid dependence medications: Prescription trends, overall and by physician specialty
Mark, T. L., Kassed, C. A., Vandivort-Warren, R., Levit, K. R., & Kranzler, H. R. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.07.018 · Cited by 246 · cited 1×
“to significantly reduce both the risk of return to any drinking and return to binge drinking [36]; however, both of these associations were modest in magnitude [64].”
BackgroundMitchell, J. M., O’Neil, J. P., Janabi, M., Marks, S. M., Jagust, W. J., & Fields, H. L. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002902 · Cited by 237 · cited 2×
“By attenuating alcohol-induced opioidergic activity in the mesolimbic dopamine system, opioid antagonists like naltrexone, modulate the rewarding effects of alcohol (mediated by dopamine), thereby reducing alcohol consumption [50, 51].”
BackgroundHuman Aldehyde Dehydrogenase: Mechanism of Inhibition of Disulfiram
Vallari, R. C., & Pietruszko, R. (1982) · Science · doi:10.1126/science.7071604 · Cited by 234 · cited 1×
“Acetaldehyde, a toxic metabolite of ethanol, produces an alcohol-induced aversive response, characterized by nausea, vomiting, sweating, flushing, and heart palpitations [23].”
BackgroundSex Differences in Alcohol Use Disorder
Agabio, R., Pisanu, C., Gessa, G. L., & Franconi, F. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867323666161202092908 · Cited by 230
Mizuno, T., Kurotani, T., Komatsu, Y., Kawanokuchi, J., Kato, H., Mitsuma, N., & Suzumura, A. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.009 · Cited by 228 · cited 1×
“Ibudilast has been shown to dose-dependently suppress pro-inflammatory cytokines, such as interleukins IL-1β, IL-6, and tumor necrosis factor alpha (TNF-α), and to increase the anti-inflammatory cytokine IL-10 and neurotrophic factors [185].”
BackgroundStreeton, C. (2001) · Alcohol and Alcoholism · doi:10.1093/alcalc/36.6.544 · Cited by 228 · cited 1×
“Additionally, clinical trials of naltrexone often yield modest effect sizes [63].”
BackgroundGlucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals
Vendruscolo, L. F., Estey, D., Goodell, V., Macshane, L. G., Logrip, M. L., Schlosburg, J. E., McGinn, M. A., Zamora-Martinez, E. R., Belanoff, J. K., Hunt, H. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79828 · Cited by 218 · cited 2×
“Preclinically, both systemic and central amygdala injections of mifepristone were shown to suppress yohimbine stress-induced reinstatement of alcohol seeking, indicating that the central amygdala plays an important role in mifepristone’s effects on ethanol-seeking [177, 178].”
BackgroundChick, J. (2000) · Alcohol and Alcoholism · doi:10.1093/alcalc/35.2.176 · Cited by 213
MASON, B., GOODMAN, A., CHABAC, S., & LEHERT, P. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.02.002 · Cited by 212
Naltrexone vs. Nefazodone for Treatment of Alcohol Dependence A Placebo-Controlled Trial
Kranzler, H. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00135-9 · Cited by 209 · cited 1×
“Another RCT reported no significant differences between naltrexone and placebo (N = 183), and that the clinical utility of naltrexone was limited by its adverse effects [62].”
BackgroundUrwyler, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.109.002501 · Cited by 207
Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast
Cho, Y., Crichlow, G. V., Vermeire, J. J., Leng, L., Du, X., Hodsdon, M. E., Bucala, R., Cappello, M., Gross, M., Gaeta, F., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002716107 · Cited by 204 · cited 1×
“Ibudilast is an inhibitor of phosphodiesterases (PDE)-3, -4, -10, and -11 [183] and macrophage migration inhibitory factor (MIF) [184].”
BackgroundFreeman, T. P., Hindocha, C., Baio, G., Shaban, N. D. C., Thomas, E. M., Astbury, D., Freeman, A. M., Lees, R., Craft, S., Morrison, P. D., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30290-x · Cited by 203 · cited 1×
“Two recent studies investigated signals for potential efficacy of CBD as a treatment for heroin use disorder [281] and cannabis use disorder [282].”
BackgroundNaltrexone for alcohol dependence: a randomized controlled trial
Morris, P. L. P., Hopwood, M., Whelan, G., Gardiner, J., & Drummond, E. (2001) · Addiction · doi:10.1046/j.1360-0443.2001.961115654.x · Cited by 200 · cited 1×
“Additional recent trials demonstrate that naltrexone reduces the rewarding effects of alcohol [54, 55], alcohol craving [40, 56], drinks per drinking day [57], and relapse rates [58, 59], strengthening the initial findings.”
Martínez-Pinilla, E., Varani, K., Reyes-Resina, I., Angelats, E., Vincenzi, F., Ferreiro-Vera, C., Oyarzabal, J., Canela, E. I., Lanciego, J. L., Nadal, X., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00744 · Cited by 199 · cited 1×
“CB1 and CB2 receptors [274, 275], and blocking anandamide update and inhibiting enzymatic hydrolysis [276].”
BackgroundTramadol for neuropathic pain in adults
Duehmke, R. M., Derry, S., Wiffen, P. J., Bell, R. F., Aldington, D., & Moore, R. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003726.pub4 · Cited by 191
A Meta-Analysis of Topiramate's Effects for Individuals with Alcohol Use Disorders
Blodgett, J. C., Del Re, A. C., Maisel, N. C., & Finney, J. W. (2014) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12411 · Cited by 188 · cited 2×
“A meta-analysis including seven RCTs of topiramate for AUD with a total of 1125 participants found that topiramate significantly increased number of days abstinence and decreased heavy-drinking days compared to placebo [118].”
MethodResultAnton, R. F., Latham, P., Voronin, K., Book, S., Hoffman, M., Prisciandaro, J., & Bristol, E. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0249 · Cited by 186 · cited 2×
“While these findings may be related to potential pharmacokinetic issues relating to the specific formulation of extended-release gabapentin used in the trial, it is also possible that gabapentin may simply be more effective in patients with more clinically relevant and severe symptoms of alcohol withdrawal [130, 134].”
BackgroundEpidemiologic analysis of alcohol and tobacco use.
Anthony, J. C., & Echeagaray-Wagner, F. (2000) · PubMed Central · Cited by 184
Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism
Kranzler, H. R., Covault, J., Feinn, R., Armeli, S., Tennen, H., Arias, A. J., Gelernter, J., Pond, T., Oncken, C., & Kampman, K. M. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13081014 · Cited by 184
Harm reduction -a systematic review on effects of alcohol reduction on physical and mental symptoms
Charlet, K., & Heinz, A. (2017) · Addiction Biology · doi:10.1111/adb.12414 · Cited by 183
Does disulfiram have a role in alcoholism treatment today?
FULLER, R. K., & GORDIS, E. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00597.x · Cited by 182 · cited 1×
“Disulfiram ingestion under supervision (to ensure adherence) saw significantly better success rates compared to non-supervised treatment, suggesting that supervised administration of disulfiram may still have a place in treating individuals struggling to attain sobriety [33], and unsupervised disulfiram may also be he…”
BackgroundBrower, K. J., Myra Kim, H., Strobbe, S., Karam‐Hage, M. A., Consens, F., & Zucker, R. A. (2008) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00706.x · Cited by 179 · cited 1×
“In another 10-day study with 21 participants, gabapentin significantly delayed return to heavy drinking [127].”
BackgroundChoosing appropriate language to reduce the stigma around mental illness and substance use disorders
Volkow, N. D., Gordon, J. A., & Koob, G. F. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01069-4 · Cited by 175 · cited 1×
“Researchers and clinicians can help in these efforts by reducing stigma surrounding AUD and other substance use disorders by choosing appropriate language to describe these disorders and the people who are affected by them [285].”
BackgroundNeuropharmacological treatments for alcoholism: scientific basis and clinical findings
Johnson, B. A., & Ait-Daoud, N. (2000) · Psychopharmacology · doi:10.1007/s002130000371 · Cited by 172
Palpacuer, C., Duprez, R., Huneau, A., Locher, C., Boussageon, R., Laviolle, B., & Naudet, F. (2018) · Addiction · doi:10.1111/add.13974 · Cited by 172 · cited 1×
“Overall, while nalmefene may reduce heavy-drinking rates, its effects on other outcomes [77] remain small-to-moderate, and study withdrawals related to adverse events are common in nalmefene trials.”
BackgroundSerotonin-3 receptor and ethanol-stimulated dopamine release in the nucleus accumbens
Campbell, A. D., & McBride, W. J. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)00050-7 · Cited by 170 · cited 1×
“Preclinically, 5-HT3 antagonism has been shown to block acquisition and maintenance of ethanol self-administration [165] and reduce ethanol-associated dopamine concentration in the nucleus accumbens [166].”
BackgroundShoblock, J. R., Welty, N., Aluisio, L. E., Fraser, I. C., Motley, S. T., Morton, K. L., Palmer, J. A., Bonaventure, P., Carruthers, N. I., Lovenberg, T. W., et al. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2127-x · Cited by 167
α1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol
Walker, B. M., Rasmussen, D. D., Raskind, M. A., & Koob, G. F. (2008) · Alcohol · doi:10.1016/j.alcohol.2007.12.002 · Cited by 167 · cited 1×
“Preclinical work found that prazosin reduced ethanolrelated operant responding in acute withdrawal for dependent, but not non-dependent rodents [201].”
BackgroundDisulfiram treatment of alcoholism. A Veterans Administration cooperative study.
Fuller, R. K., Branchey, L., Brightwell, D. R., Derman, R., Emrick, C. D., Iber, F. L., James, K. E., Lacoursiere, R. B., Lee, K. K., & Lowenstam, I. (1986) · PubMed · Cited by 166
Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease
Leggio, L., & Lee, M. R. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.10.004 · Cited by 166 · cited 1×
“Treatment options for individuals with AALD are limited; of the FDA-approved medications, only acamprosate can be used without concerns of hepatotoxicity [296].”
BackgroundPierce, M., Sutterland, A., Beraha, E. M., Morley, K., & van den Brink, W. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.03.017 · Cited by 165 · cited 2×
“Furthermore, greater alcohol use at baseline was correlated with a greater treatment effect [85].”
BackgroundBart, G. B., Schluger, J. H., Borg, L., Ho, A., Bidlack, J. M., & Kreek, M. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300811 · Cited by 163 · cited 1×
“Nalmefene works in a similar manner to naltrexone as an antagonist at the mu and delta opioid receptor, but is also a kappa opioid receptor partial agonist [68].”
BackgroundGamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses
Leone, M. A., Vigna-Taglianti, F., Avanzi, G., Brambilla, R., & Faggiano, F. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006266.pub2 · Cited by 163 · cited 1×
“A Cochrane meta-analysis of 13 RCTs with a total of 649 participants found that SMO (50 mg) was effective compared to placebo in the treatment of alcohol withdrawal syndrome (AWS) and in preventing relapses in previously detoxified participants, and that SMO was more effective than naltrexone and disulfiram in maintai…”
MethodLeggio, L., Zywiak, W. H., Fricchione, S. R., Edwards, S. M., de la Monte, S. M., Swift, R. M., & Kenna, G. A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.019 · Cited by 162 · cited 1×
“In human laboratory studies, intravenous ghrelin administration has been shown to increase the urge to drink, increase alcohol self-administration, and modulate brain activity in regions involved in reward processing and stress regulation [264, 265].”
BackgroundThe inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family
Gibson, L. C. D., Hastings, S. F., McPhee, I., Clayton, R. A., Darroch, C. E., MacKenzie, A., MacKenzie, F. L., Nagasawa, M., Stevens, P. A., & MacKenzie, S. J. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.053 · Cited by 159
A Pilot Trial of the Alpha‐1 Adrenergic Antagonist, Prazosin, for Alcohol Dependence
Simpson, T. L., Saxon, A. J., Meredith, C. W., Malte, C. A., McBride, B., Ferguson, L. C., Gross, C. A., Hart, K. L., & Raskind, M. (2009) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00807.x · Cited by 159 · cited 1×
“In humans, an early 6-week pilot study with 24 randomized participants with AUD revealed that prazosin treatment was associated with fewer drinking days per week and fewer drinks per week than placebo [206].”
BackgroundGabapentin Combined With Naltrexone for the Treatment of Alcohol Dependence
Anton, R. F., Myrick, H., Wright, T. M., Latham, P. K., Baros, A. M., Waid, L. R., & Randall, P. K. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10101436 · Cited by 157 · cited 1×
“, decreased heavy-drinking days, fewer drinks per drinking day, and delayed time to heavy drinking) compared with naltrexone alone in a 6-week trial with 150 participants [131].”
BackgroundBaclofen for the treatment of alcohol use disorder: the Cagliari Statement
Agabio, R., Sinclair, J., Addolorato, G., Aubin, H., Beraha, E. M., Caputo, F., Chick, J., Selle, P. D. L., Franchitto, N., Garbutt, J. C., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30303-1 · Cited by 153 · cited 1×
“It was approved for treatment of AUD in France in 2018 [78] and has been used off-label for AUD for over a decade in other countries, especially other European countries and Australia [79, 80].”
MethodWitkiewitz, K. A., Kranzler, H. R., Hallgren, K. A., O’Malley, S. S., Falk, D. E., Litten, R. Z., Hasin, D. S., Mann, K. F., & Anton, R. F. (2018) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13897 · Cited by 152 · cited 1×
“Recent work has found that harm reduction endpoints, including reductions in WHObased drinking levels [286], are associated with improvements in physical health and quality of life [287] and can be used as efficacy outcomes in clinical trials [288].”
BackgroundReynaud, M., Aubin, H.-J., Trinquet, F., Zakine, B., Dano, C., Dematteis, M., Trojak, B., Paille, F., & Detilleux, M. (2017) · Alcohol and Alcoholism · doi:10.1093/alcalc/agx030 · Cited by 145
Furieri, F. A., & Nakamura-Palacios, E. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1108 · Cited by 144 · cited 1×
“Gabapentin reduced percent heavy-drinking days and drinks per day, as well as increased percentage abstinent days in a 28-day trial with 60 participants [126].”
BackgroundDrobes, D. J., Anton, R. F., Thomas, S. E., & Voronin, K. (2004) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000139704.88862.01 · Cited by 140 · cited 1×
“Additional recent trials demonstrate that naltrexone reduces the rewarding effects of alcohol [54, 55], alcohol craving [40, 56], drinks per drinking day [57], and relapse rates [58, 59], strengthening the initial findings.”
Hasin, D. S., Wall, M., Witkiewitz, K., Kranzler, H. R., Falk, D., Litten, R., Mann, K., O'Malley, S. S., Scodes, J., Robinson, R. L., et al. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30130-x · Cited by 140 · cited 1×
“Recent work has found that harm reduction endpoints, including reductions in WHObased drinking levels [286], are associated with improvements in physical health and quality of life [287] and can be used as efficacy outcomes in clinical trials [288].”
BackgroundBell, R. L., Lopez, M. F., Cui, C., Egli, M., Johnson, K. W., Franklin, K. M., & Becker, H. C. (2015) · Addiction Biology · doi:10.1111/adb.12106 · Cited by 138 · cited 1×
“Preclinically, ibudilast was demonstrated to reduce alcohol intake in two rat models, and decreased drinking selectively in alcohol-dependent mice in comparison to nondependent mice [188].”
BackgroundColombo, G., Addolorato, G., Agabio, R., Carai, M. A. M., Pibiri, F., Serra, S., Vacca, G., & Gessa, G. L. (2004) · Neurotoxicity Research · doi:10.1007/bf03033315 · Cited by 137
Rose, A. K., & Jones, A. (2018) · Addiction · doi:10.1111/add.14191 · Cited by 137 · cited 1×
“A recent meta-analysis of 12 RCTs (N = 703) showed that baclofen in comparison to placebo was associated with higher abstinence rates [81–83]; however, it did not increase abstinent days or decrease craving, heavy drinking, depression, or anxiety [84].”
BackgroundState-of-the-art behavioral and pharmacological treatments for alcohol use disorder
Ray, L. A., Bujarski, S., Grodin, E., Hartwell, E., Green, R., Venegas, A., Lim, A. C., Gillis, A., & Miotto, K. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1528265 · Cited by 137 · cited 1×
“These medications are only modestly effective [13] and are under-utilized in treatment.”
BackgroundSelf-citationBarson, J. R., Ho, H. T., & Leibowitz, S. F. (2015) · Addiction Biology · doi:10.1111/adb.12139 · Cited by 134
FRANCES, R. J. (2007) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70391-8 · Cited by 134
Han, B., Jones, C. M., Einstein, E. B., Powell, P. A., & Compton, W. M. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.1271 · Cited by 134 · cited 2×
“6% of adults in the USA with past-year AUD received evidence-based AUD pharmacotherapies [14].”
BackgroundNealey, K. A., Smith, A. W., Davis, S. M., Smith, D. G., & Walker, B. M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.02.012 · Cited by 133 · cited 1×
“Via its kappa agonist activity, particularly centered in dopaminergic nucleus accumbens circuitry, nalmefene may reduce motivation for self-administration and withdrawal-induced alcohol consumption [69, 70].”
Backgroundα1-Adrenergic Receptors in Neurotransmission, Synaptic Plasticity, and Cognition
Perez, D. M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.581098 · Cited by 130 · cited 1×
“Adrenergic receptors regulate sympathetic nervous system activity through activation of the neurotransmitter norepinephrine [199].”
BackgroundEffects of Ondansetron in Early‐ Versus Late‐Onset Alcoholics: A Prospective, Open‐Label Study
Kranzler, H. R., Pierucci‐Lagha, A., Feinn, R., & Hernandez‐Avila, C. (2003) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000075547.77464.76 · Cited by 129 · cited 1×
“, Drinker Inventory of Consequences; DrInC) were significantly decreased among those with early-onset AUD compared to those with late-onset AUD [173].”
ResultLee, M. R., Tapocik, J. D., Ghareeb, M., Schwandt, M. L., Dias, A. A., Le, A. N., Cobbina, E., Farinelli, L. A., Bouhlal, S., Farokhnia, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0064-y · Cited by 129 · cited 1×
“Additionally, when administered in combination with alcohol, PF-5190457 was safe and well-tolerated with no drug-alcohol interactions [272].”
BackgroundPharmacotherapy of Alcohol Use Disorders: Seventy-Five Years of Progress
Zindel, L. R., & Kranzler, H. R. (2014) · Journal of Studies on Alcohol and Drugs, Supplement · doi:10.15288/jsads.2014.75.79 · Cited by 128
Cellular and behavioral interactions of gabapentin with alcohol dependence
Roberto, M., Gilpin, N. W., O'Dell, L. E., Cruz, M. T., Morse, A. C., Siggins, G. R., & Koob, G. F. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0575-08.2008 · Cited by 126 · cited 1×
“Preclinical studies of gabapentin’s effects on ethanol consumption have shown mixed results, with some studies finding that gabapentin reduced ethanol intake in alcoholdependent rodents [123] and others finding that it increased self-administration and binge-like drinking [124, 125].”
ResultFarokhnia, M., Grodin, E. N., Lee, M. R., Oot, E. N., Blackburn, A. N., Stangl, B. L., Schwandt, M. L., Farinelli, L. A., Momenan, R., Ramchandani, V. A., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.226 · Cited by 125 · cited 1×
“In human laboratory studies, intravenous ghrelin administration has been shown to increase the urge to drink, increase alcohol self-administration, and modulate brain activity in regions involved in reward processing and stress regulation [264, 265].”
BackgroundSelf-citationBaclofen suppresses motivation to consume alcohol in rats
Colombo, G., Vacca, G., Serra, S., Brunetti, G., Carai, M. A. M., & Gessa, G. L. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1397-y · Cited by 122
Kaur, S., & Ryabinin, A. E. (2010) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01237.x · Cited by 122
A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder
Kranzler, H. R., Feinn, R., Morris, P., & Hartwell, E. E. (2019) · Addiction · doi:10.1111/add.14655 · Cited by 121 · cited 1×
“, relapse, drinks per day, complete abstinence, percent days abstinent, and concentration of gamma-glutamyl transferase (GGT)) [133].”
BackgroundFalk, D. E., O’Malley, S. S., Witkiewitz, K., Anton, R. F., Litten, R. Z., Slater, M., Kranzler, H. R., Mann, K. F., Hasin, D. S., Johnson, B., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3079 · Cited by 120 · cited 1×
“Recent work has found that harm reduction endpoints, including reductions in WHObased drinking levels [286], are associated with improvements in physical health and quality of life [287] and can be used as efficacy outcomes in clinical trials [288].”
BackgroundDahchour, A., & Witte, P. D. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02851-0 · Cited by 119
Morley, K. C., Baillie, A., Fraser, I., Furneaux-Bate, A., Dore, G., Roberts, M., Abdalla, A., Phung, N., & Haber, P. S. (2018) · The British Journal of Psychiatry · doi:10.1192/bjp.2018.13 · Cited by 119 · cited 2×
“Some of these appear to have particular promise in specific cases, such as varenicline’s use for nicotine and alcohol co-users [147], baclofen for individuals with liver disease [93], and aripiprazole for more impulsive individuals [156].”
BackgroundRay, L. A., Bujarski, S., Shoptaw, S., Roche, D. J., Heinzerling, K., & Miotto, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.10 · Cited by 118 · cited 1×
“Additionally, ibudilast improved mood during exposure to alcohol and stress cues, and reduced the mood-altering and stimulant effects of alcohol among participants with more severe depressive symptoms [192].”
BackgroundSelf-citationLandgren, S., Simms, J. A., Hyytiä, P., Engel, J. A., Bartlett, S. E., & Jerlhag, E. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00280.x · Cited by 117
Noradrenergic targets for the treatment of alcohol use disorder
Haass-Koffler, C. L., Swift, R. M., & Leggio, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4843-6 · Cited by 117
Effectiveness and Safety of Baclofen in the Treatment of Alcohol Dependent Patients
Leggio, L., Garbutt, J., & Addolorato, G. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710790966614 · Cited by 116 · cited 1×
“It was approved for treatment of AUD in France in 2018 [78] and has been used off-label for AUD for over a decade in other countries, especially other European countries and Australia [79, 80].”
MethodMason, B. J., Light, J. M., Williams, L. D., & Drobes, D. J. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00133.x · Cited by 115 · cited 1×
“In a proof-of-concept one-week human laboratory trial (N = 33), participants treated with gabapentin showed significant decreases in alcohol craving in comparison to placebo [128], and a follow-up 12-week RCT with 150 participants found that gabapentin significantly increased abstinence rates and percentage of no heav…”
BackgroundHenssler, J. F., Müller, M., Carreira, H., Bschor, T., Heinz, A., & Baethge, C. (2020) · Addiction · doi:10.1111/add.15329 · Cited by 114 · cited 1×
“Furthermore, evidence does not support abstinence as the only approach in the treatment of AUD [16].”
BackgroundOndansetron reduces the craving of biologically predisposed alcoholics
Johnson, B. A., Roache, J. D., Ait‐Daoud, N., Zanca, N. A., & Velázquez, M. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1002-9 · Cited by 109
Pharmacogenetic Randomized Trial for Cocaine Abuse: Disulfiram and Dopamine β-Hydroxylase
Kosten, T. R., Wu, G., Huang, W., Harding, M. J., Hamon, S. C., Lappalainen, J., & Nielsen, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.07.011 · Cited by 108 · cited 1×
“Disulfiram may also act on dopamine systems, as its major metabolite inhibits the enzyme dopamine betahydroxylase (DBH), which aids in metabolizing dopamine into noradrenaline [22, 26, 27].”
BackgroundAnton, R. F., Kranzler, H., Breder, C., Marcus, R. N., Carson, W. H., & Han, J. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181602fd4 · Cited by 106 · cited 1×
“Another multicenter RCT enrolling 295 participants over 12 weeks found no significant difference between the aripiprazole and placebo groups in percentage of participants completely abstinent from alcohol throughout the study or time to first drinking day; however, the average number of drinks per drinking day was sig…”
BackgroundRasmussen, D. D., Alexander, L. L., Raskind, M. A., & Froehlich, J. C. (2009) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00829.x · Cited by 106
Varenicline for Treatment of Alcohol Dependence: A Randomized, Placebo‐Controlled Trial
de Bejczy, A., Löf, E., Walther, L., Guterstam, J., Hammarberg, A., Asanovska, G., Franck, J., Isaksson, A., & Söderpalm, B. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12854 · Cited by 105 · cited 1×
“However, a 12-week RCT (N = 160) found no effect of varenicline over placebo on heavy-drinking days [143], and a recent 6-week human laboratory study in 47 participants found that varenicline did not significantly attenuate cueinduced alcohol craving relative to placebo [144].”
BackgroundEdwards, S., Guerrero, M., Ghoneim, O. M., Roberts, E., & Koob, G. F. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00291.x · Cited by 104 · cited 1×
“V1B antagonists attenuate basal hypothalamic-pituitary-adrenal (HPA) axis activity and have shown favorable effects in rat models of alcohol dependence, including attenuating reinstatement of alcohol self-administration [241], and diminishing alcohol intake by alcohol-preferring and alcohol-dependent rats [241, 242].”
BackgroundFan, A. Z., Chou, S. P., Zhang, H., Jung, J., & Grant, B. F. (2019) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.14192 · Cited by 104 · cited 1×
“While abstinence may be desirable, it is infrequently obtained, such that only 16% of individuals in treatment for AUD achieve abstinence [15].”
BackgroundAcamprosate: A Prototypic Neuromodulator in the Treatment of Alcohol Dependence
Mason, B., & Heyser, C. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710790966641 · Cited by 103 · cited 1×
“While the specific mechanisms through which acamprosate works to treat AUD remain under investigation, it is thought to act on the glutamatergic system as an N-methyl-d-aspartic acid (NMDA) receptor partial co-agonist [35].”
BackgroundVenegas, A., Donato, S., Meredith, L. R., & Ray, L. A. (2021) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2021.1969658 · Cited by 103 · cited 1×
“First, despite the prevalence of AUD, the rate of seeking treatment for AUD remains very low [284].”
BackgroundSelf-citationMartinotti, G., Di Nicola, M., Di Giannantonio, M., & Janiri, L. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089596 · Cited by 102 · cited 1×
“A 16-week RCT directly comparing aripiprazole against naltrexone (N = 75) found that the two medications were overall comparable in reducing heavy-drinking days and increasing days of abstinence, although patients treated with naltrexone had reduced craving compared to aripiprazole [157].”
BackgroundBaclofen for the Treatment of Alcohol Dependence and Possible Role of Comorbid Anxiety
Morley, K. C., Baillie, A., Leung, S., Addolorato, G., Leggio, L., & Haber, P. S. (2014) · Alcohol and Alcoholism · doi:10.1093/alcalc/agu062 · Cited by 102
Palpacuer, C., Laviolle, B., Boussageon, R., Reymann, J. M., Bellissant, E., & Naudet, F. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001924 · Cited by 102 · cited 1×
“65 fewer heavy-drinking days per month than participants treated with placebo after 6 months [75].”
Brown, R. M., Khoo, S. Y.-S., & Lawrence, A. J. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000333 · Cited by 101
Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat
Spanagel, R., Putzke, J., Stefferl, A., Schöbitz, B., & Zieglgänsberger, W. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00175-6 · Cited by 100
Anderson, R. I., Becker, H. C., Adams, B. L., Jesudason, C. D., & Rorick-Kehn, L. M. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00033 · Cited by 98 · cited 1×
“Similarly, dual orexin antagonists reduce alcohol consumption in alcohol-preferring rats [237, 238].”
BackgroundGABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence
Agabio, R., & Colombo, G. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00140 · Cited by 97
Simms, J. A., Haass-Koffler, C. L., Bito-Onon, J., Li, R., & Bartlett, S. E. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.268 · Cited by 97 · cited 1×
“Preclinically, both systemic and central amygdala injections of mifepristone were shown to suppress yohimbine stress-induced reinstatement of alcohol seeking, indicating that the central amygdala plays an important role in mifepristone’s effects on ethanol-seeking [177, 178].”
BackgroundIncreased NMDA-induced excitability during ethanol withdrawal: a behavioural and histological study
Davidson, M., Shanley, B., & Wilce, P. (1995) · Brain Research · doi:10.1016/0006-8993(94)01440-s · Cited by 94 · cited 1×
“As chronic alcohol abuse is associated with neuronal changes related to NMDA receptors, this neuroprotection may be particularly important in AUD treatment [47, 48].”
BackgroundPharmacotherapy for Alcohol Use Disorder: Current and Emerging Therapies
Swift, R. M., & Aston, E. R. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000079 · Cited by 93 · cited 1×
“Placebo effects in this trial may explain some of these negative outcomes, as might differences in trial design and patient characteristics: COMBINE required 4 days of pre-trial abstinence while European trials with positive outcomes were typically conducted in inpatient populations requiring complete detoxification […”
ResultMoorman, D. E., James, M. H., Kilroy, E. A., & Aston‐Jones, G. (2016) · Brain Research · doi:10.1016/j.brainres.2016.10.018 · Cited by 93
O’Malley, S. S., Zweben, A., Fucito, L. M., Wu, R., Piepmeier, M. E., Ockert, D. M., Bold, K. W., Petrakis, I., Muvvala, S., Jatlow, P., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3544 · Cited by 93 · cited 1×
“Findings also indicate that varenicline may be more effective as an AUD treatment in men, as a 16-week RCT with 131 participants found that varenicline combined with medication management decreased percent heavy-drinking days only in men, but improved smoking abstinence in both men and women [149].”
BackgroundCurrent Findings and Mechanisms of Action of Disulfiram in the Treatment of Alcohol Dependence
Mutschler, J., Grosshans, M., Soyka, M., & Rösner, S. (2016) · Pharmacopsychiatry · doi:10.1055/s-0042-103592 · Cited by 91 · cited 1×
“Instead, a patient simply being aware of a potential adverse reaction appears to be enough to influence drinking behavior [32].”
BackgroundMann, K., Vollstädt‐Klein, S., Reinhard, I., Leménager, T., Fauth‐Bühler, M., Hermann, D., Hoffmann, S., Zimmermann, U. S., Kiefer, F., Heinz, A., et al. (2014) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12546 · Cited by 90
Johnson, B. A., Ait‐Daoud, N., & Prihoda, T. J. (2000) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2000.tb02048.x · Cited by 89 · cited 1×
“In an 8-week RCT in 20 participants with early-onset AUD, ondansetron and naltrexone (in comparison with placebo) significantly reduced drinks per drinking day and trended towards an increase in percentage of days abstinent [170].”
BackgroundFalk, D. E., Ryan, M. L., Fertig, J. B., Devine, E. G., Cruz, R., Brown, E. S., Burns, H., Salloum, I. M., Newport, D. J., Mendelson, J., et al. (2019) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13917 · Cited by 89 · cited 1×
“However, another recent 6-month multisite RCT of extended-release gabapentin conducted in 346 participants with at least moderate AUD found no effects over placebo for any clinical outcomes including abstinence rate, percent heavy-drinking days, drinks per drinking day, or alcohol craving [135].”
BackgroundSelf-citationCannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review
Turna, J., Syan, S. K., Frey, B. N., Rush, B., Costello, M. J., Weiss, M., & MacKillop, J. (2019) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13964 · Cited by 83 · cited 1×
“Evidence in healthy individuals demonstrates that CBD is well tolerated, does not interact with the subjective effects of alcohol, and has no abuse liability [280].”
BackgroundDuailibi, M. S., Cordeiro, Q., Brietzke, E., Ribeiro, M., LaRowe, S., Berk, M., & Trevizol, A. P. (2017) · The American Journal on Addictions · doi:10.1111/ajad.12620 · Cited by 82 · cited 2×
“Orally-administered NAC appears to be well tolerated, with the most common adverse effects being nausea and diarrhea [212, 222].”
BackgroundTomkins, D. M., Lê, A. D., & Sellers, E. M. (1995) · Psychopharmacology · doi:10.1007/bf02246222 · Cited by 81
O’Malley, S. S., Corbin, W. R., Leeman, R. F., DeMartini, K. S., Fucito, L. M., Ikomi, J., Romano, D. M., Wu, R., Toll, B. A., Sher, K. J., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08934 · Cited by 79 · cited 1×
“Additional recent trials demonstrate that naltrexone reduces the rewarding effects of alcohol [54, 55], alcohol craving [40, 56], drinks per drinking day [57], and relapse rates [58, 59], strengthening the initial findings.”
Grodin, E. N., Bujarski, S., Towns, B., Burnette, E., Nieto, S., Lim, A., Lin, J., Miotto, K., Gillis, A., Irwin, M. R., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01478-5 · Cited by 78 · cited 2×
“Another recent 2-week RCT enrolling 52 participants found that ibudilast also significantly decreased the odds of heavy drinking during the trial by 45% compared to placebo and attenuated neural response to alcohol cues in the ventral striatum [193, 194].”
BackgroundSelf-citationWitkiewitz, K. A., Roos, C. R., Mann, K. F., & Kranzler, H. R. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14183 · Cited by 77
Wu, Y., Lousberg, E. L., Moldenhauer, L. M., Hayball, J. D., Coller, J. K., Rice, K. C., Watkins, L. R., Somogyi, A. A., & Hutchinson, M. R. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01572.x · Cited by 76
Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder
Simpson, T. L., Saxon, A. J., Stappenbeck, C., Malte, C. A., Lyons, R., Tell, D., Millard, S. P., & Raskind, M. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17080913 · Cited by 76 · cited 1×
“More recently, 92 participants with AUD completed a 12-week double-blind study with prazosin and medication management [207].”
Gomez, J. L., Cunningham, C. L., Finn, D. A., Young, E. A., Helpenstell, L. K., Schuette, L. M., Fidler, T. L., Kosten, T. A., & Ryabinin, A. E. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.026 · Cited by 75
Anton, R. F., Myrick, H., Baros, A. M., Latham, P. K., Randall, P. K., Wright, T. M., Stewart, S. H., Waid, R., & Malcolm, R. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181aba6a4 · Cited by 75 · cited 2×
“While these findings may be related to potential pharmacokinetic issues relating to the specific formulation of extended-release gabapentin used in the trial, it is also possible that gabapentin may simply be more effective in patients with more clinically relevant and severe symptoms of alcohol withdrawal [130, 134].”
BackgroundResultHauser, P., Fuller, B., Ho, S. B., Thuras, P., Kern, S., & Dieperink, E. (2017) · Addiction · doi:10.1111/add.13787 · Cited by 75
van den Brink, W., Addolorato, G., Aubin, H., Benyamina, A., Caputo, F., Dematteis, M., Gual, A., Lesch, O., Mann, K., Maremmani, I., et al. (2018) · Addiction Biology · doi:10.1111/adb.12645 · Cited by 75 · cited 2×
“SMO craving and abuse potential may limit its use; however, at therapeutic doses, SMO abuse seems to be a relatively infrequent phenomenon among patients without psychiatric comorbidities or poly-drug use [96, 100, 105].”
BackgroundAnticonvulsants for alcohol dependence
Pani, P. P., Trogu, E., Pacini, M., & Maremmani, I. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008544.pub2 · Cited by 75 · cited 1×
“Anticonvulsants were also associated with longer time-to-relapse and fewer heavy-drinking days compared to naltrexone [132].”
BackgroundInhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice
Blednov, Y. A., Benavidez, J. M., Black, M., & Harris, R. A. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00129 · Cited by 74
Srinivasan, S., Simms, J. A., Nielsen, C. K., Lieske, S. P., Bito-Onon, J. J., Yi, H., Hopf, F. W., Bonci, A., & Bartlett, S. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044726 · Cited by 73 · cited 1×
“Similarly, dual orexin antagonists reduce alcohol consumption in alcohol-preferring rats [237, 238].”
BackgroundReview of Topiramate: An Antiepileptic for the Treatment of Alcohol Dependence
Kenna, G., Lomastro, T., Schiesl, A., Leggio, L., & Swift, R. (2009) · Current Drug Abuse Reviewse · doi:10.2174/1874473710902020135 · Cited by 73 · cited 1×
“It is worth noting a potential strength of topiramate: the possibility of starting treatment while patients are still actively drinking, allowing topiramate to serve as a harmreduction or abstinence-initiation treatment, rather than only being used to prevent relapse in already detoxified patients [120].”
BackgroundBaclofen for alcohol use disorder
Minozzi, S., Saulle, R., & Rösner, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012557.pub2 · Cited by 73 · cited 1×
“, anxiety and craving); however, baclofen did increase depression and adverse effects including sedation and vertigo [86].”
BackgroundKnapp, C. M., Ciraulo, D. A., Sarid-Segal, O., Richardson, M. A., Devine, E., Streeter, C. C., Oscar-Berman, M., Surprise, C., Colaneri, L., Putnam, M., et al. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000246 · Cited by 72
Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
Richardson, K., Baillie, A., Reid, S., Morley, K., Teesson, M., Sannibale, C., Weltman, M., & Haber, P. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02215.x · Cited by 72
The Effect of Aripiprazole on Cue-Induced Brain Activation and Drinking Parameters in Alcoholics
Myrick, H., Li, X., Randall, P. K., Henderson, S., Voronin, K., & Anton, R. F. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181e75cff · Cited by 72 · cited 1×
“In a sample of 30 participants with AUD, aripiprazole compared to placebo, was found to attenuate cue-induced neural activation in the ventral striatum, a region associated with reward [155].”
Backgroundfor the National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group, Ryan, M. L., Falk, D. E., Fertig, J. B., Rendenbach-Mueller, B., Katz, D. A., Tracy, K. A., Strain, E. C., Dunn, K. E., Kampman, K., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.214 · Cited by 72
N-acetylcysteine Prevents Alcohol Related Neuroinflammation in Rats
Schneider, R., Bandiera, S., de Souza, D. G., Bellaver, B., Caletti, G., Quincozes‐Santos, A., Elisabetsky, E., & Gomez, R. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2218-8 · Cited by 72
Wen, R., Zhang, M., Qin, W., Liu, Q., Wang, W., Lawrence, A. J., Zhang, H., & Liang, J. (2012) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2012.01845.x · Cited by 71
Rolan, P., Gibbons, J. A., He, L., Chang, E., Jones, D., Gross, M. I., Davidson, J. B., Sanftner, L. M., & Johnson, K. W. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03270.x · Cited by 70 · cited 1×
“Ibudilast appears to be well tolerated [195], with common adverse side effects including gastrointestinal symptoms (nausea, vomiting, abdominal pain, and diarrhea),”
BackgroundLitten, R. Z., Falk, D. E., Ryan, M. L., & Fertig, J. B. (2016) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13093 · Cited by 69 · cited 1×
“Medication development has been identified as a critical priority for AUD research [283].”
BackgroundEffect of N‐acetylcysteine on motivation, seeking and relapse to ethanol self‐administration
Lebourgeois, S., González‐Marín, M. C., Jeanblanc, J., Naassila, M., & Vilpoux, C. (2018) · Addiction Biology · doi:10.1111/adb.12521 · Cited by 69 · cited 2×
“Additionally, NAC reduced ethanol-seeking and self-administration in rodents [215, 216].”
BackgroundTargeting liver aldehyde dehydrogenase-2 prevents heavy but not moderate alcohol drinking
Guillot, A., Ren, T., Jourdan, T., Pawlosky, R. J., Han, E., Kim, S.-J., Zhang, L., Koob, G. F., & Gao, B. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908137116 · Cited by 68
Garbutt, J. C., Kampov-Polevoy, A. B., Pedersen, C., Stansbury, M., Jordan, R., Willing, L., & Gallop, R. J. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01055-w · Cited by 68 · cited 1×
“Additionally, dose and sex may moderate baclofen tolerability and response; escalation of dosage in response to developing tolerance can increase sedative side effects, which affect women significantly more than men at the same dose [91].”
BackgroundKenna, G. A., Haass-Koffler, C. L., Zywiak, W. H., Edwards, S. M., Brickley, M. B., Swift, R. M., & Leggio, L. (2016) · Addiction Biology · doi:10.1111/adb.12275 · Cited by 67 · cited 1×
“, drinks per week, heavy-drinking days) [208].”
Acamprosate in Alcohol Dependence: Implications of a Unique Mechanism of Action
Littleton, J. M. (2007) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e318156c26f · Cited by 67 · cited 1×
“Acamprosate is generally well tolerated [34] and may also have neuroprotective effects [45, 46].”
BackgroundAnticraving therapy for alcohol use disorder: A clinical review
Shen, W. W. (2018) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12028 · Cited by 67 · cited 1×
“Mifepristone (RU-486), a glucocorticoid receptor antagonist, works on the stress system by regulating the amygdala [176].”
BackgroundChen, X., Michaelis, M. L., & Michaelis, E. K. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69041559.x · Cited by 65
Augier, E., Dulman, R. S., Damadzic, R., Pilling, A., Hamilton, J. P., & Heilig, M. A. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.53 · Cited by 64
Brown, R. M., Kim, A. K., Khoo, S. Y.-S., Kim, J. H., Jupp, B., & Lawrence, A. J. (2016) · Addiction Biology · doi:10.1111/adb.12251 · Cited by 63
Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome.
Busardò, F. P., Kyriakou, C., Napoletano, S., Marinelli, E., & Zaami, S. (2015) · PubMed · Cited by 62
de Ternay, J., Naassïla, M., Nourredine, M., Louvet, A., Bailly, F., Sescousse, G., Maurage, P., Cottencin, O., Carrieri, P., & Rolland, B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00627 · Cited by 62 · cited 1×
“Preclinical studies have shown that CBD reduces alcohol administration, decreases motivation for alcohol, reduces relapse-like behavior, and improves withdrawal symptoms in animals exposed to chronic alcohol [279].”
BackgroundFalk, D. E., Castle, I.-J. P., Ryan, M., Fertig, J., & Litten, R. Z. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000133 · Cited by 59 · cited 2×
“Moderator analyses of data collected in the above multisite trial [142] indicated that varenicline was more efficacious in reducing drinking among smokers who also reduced their cigarette smoking [147] and among individuals with lower severity of AUD, such that that varenicline significantly reduced percent heavy-drin…”
BackgroundZhou, Y., Colombo, G., Carai, M. A. M., Ho, A., Gessa, G. L., & Kreek, M. J. (2011) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01532.x · Cited by 57 · cited 1×
“V1B antagonists attenuate basal hypothalamic-pituitary-adrenal (HPA) axis activity and have shown favorable effects in rat models of alcohol dependence, including attenuating reinstatement of alcohol self-administration [241], and diminishing alcohol intake by alcohol-preferring and alcohol-dependent rats [241, 242].”
BackgroundN-acetylcysteine prevents behavioral and biochemical changes induced by alcohol cessation in rats
Schneider, R., Santos, C. F., Clarimundo, V. S., Dalmaz, C., Elisabetsky, E., & Gomez, R. (2015) · Alcohol · doi:10.1016/j.alcohol.2015.01.009 · Cited by 57
Potential Neuroprotective Effects of Acamprosate
Koob, G. F., Mason, B. J., De Witte, P., Littleton, J., & Siggins, G. R. (2002) · Alcoholism: Clinical and Experimental Research · doi:10.1097/00000374-200204000-00021 · Cited by 57 · cited 1×
“Acamprosate is generally well tolerated [34] and may also have neuroprotective effects [45, 46].”
BackgroundDenney, W. S., Sonnenberg, G. E., Carvajal‐Gonzalez, S., Tuthill, T., & Jackson, V. M. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13127 · Cited by 57 · cited 1×
“PF-5190457 may increase somnolence, heart rate, and lower blood glucose concentrations [273], although clinical results indicate that these side effects were not exacerbated by alcohol co-administration and in general PF-5190457 is well tolerated.”
BackgroundThe effect of N-acetylcysteine on alcohol use during a cannabis cessation trial
Squeglia, L. M., Tomko, R. L., Baker, N. L., McClure, E. A., Book, G. A., & Gray, K. M. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.12.005 · Cited by 57 · cited 1×
“, drinks per week and drinking days per week) by 30% [223].”
BackgroundWitkiewitz, K. A., Wilson, A. D., Roos, C. R., Swan, J. E., Votaw, V. R., Stein, E., Pearson, M. R., Edwards, K. A., Tonigan, J. S., Hallgren, K. A., et al. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000760 · Cited by 57 · cited 1×
“Indeed, non-abstinent AUD recovery has been shown to be sustainable for up to 10 years following treatment [21].”
BackgroundInfluentialPhosphodiesterase 10A Regulates Alcohol and Saccharin Self-Administration in Rats
Logrip, M. L., Vendruscolo, L. F., Schlosburg, J. E., Koob, G. F., & Zorrilla, E. P. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.20 · Cited by 56
Skala, K., Caputo, F., Mirijello, A., Vassallo, G., Antonelli, M., Ferrulli, A., Walter, H., Lesch, O., & Addolorato, G. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.863278 · Cited by 55 · cited 11×
“However, the drug is thought to inhibit glutamate α-amino 3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) and kainate receptors [108–110] and L-type calcium channels [111], as well as enhance the inhibitory activity of GABA [109].”
BackgroundInfluential
Cited by
Volkow, N. D., & Blanco, C. (2023) · World psychiatry · doi:10.1002/wps.21073 · Cited by 503
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Dharavath, R. N., Pina‐Leblanc, C., Tang, V. M., Sloan, M. E., Nikolova, Y. S., Pangarov, P., Ruocco, A. C., Shield, K. D., Voineskos, D., Blumberger, D. M., et al. (2023) · Frontiers in Neural Circuits · doi:10.3389/fncir.2023.1218737 · Cited by 92
Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
van der Pol, K. H., Aljofan, M., Blin, O., Cornel, J. H., Rongen, G. A. P. J. M., Woestelandt, A.-G. B., & Spedding, M. (2023) · Applied Health Economics and Health Policy · doi:10.1007/s40258-023-00816-6 · Cited by 68
Baclofen for alcohol use disorder
Agabio, R., Saulle, R., Rösner, S., & Minozzi, S. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012557.pub3 · Cited by 77
Metadata
- Authors
- Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A.
- Affiliations
- University of California, Los Angeles (US)
- Los Angeles County Department of Public Health (US)
- Corresponding author
- Ray, Lara A.
- ORCID
- Venue
- Drugs
- Published
- 2022-02
- Volume
- 82
- Issue
- 3
- Pages
- 251-274
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC8888464
- OpenAlex
- W4210944481
- Cited by
- 169
- References
- 318
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 52 · 2023: 35 · 2022: 14
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor, 7 d)
- Locations
- Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (K24AA025704, F31AA028976, F32AA029288)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- alcoholism, pharmacotherapy, drug repurposing, disulfiram, acamprosate, naltrexone, nalmefene, topiramate, gabapentin, varenicline, baclofen, sodium oxybate, aripiprazole, ondansetron, mifepristone, ibudilast, suvorexant, prazosin, doxazosin, N-acetylcysteine, cannabidiol, precision medicine, treatment access, treatment seeking
- MeSH terms
- Topiramate, Acamprosate, Alcohol Deterrents, Alcoholism, Baclofen, Disulfiram, Humans, Naltrexone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.